Observational studyJournal of cachexia, sarcopenia and muscle2026
Diagnostic Utility of Muscle Ultrasound for Sarcopenia in Prader-Willi Syndrome: A Cross-Sectional Study.
Observational study in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrader-Willi syndrome (PWS) is characterized by sarcopenic obesity; however, validated screening tools for muscle mass in clinical settings are lacking. This study aimed to evaluate the diagnostic utility of muscle ultrasound (US) for detecting low muscle mass in individuals with PWS.
methodsThis observational, cross-sectional study recruited 48 individuals with genetically confirmed PWS (International Classification of Diseases, 10th Revision Code Q87.1) from a specialized clinic (October 2022-June 2024). Appendicular skeletal muscle index (ASMI) via dual-energy x-ray absorptiometry (DXA) served as the primary outcome. Sarcopenia was defined based on Asian Working Group for Sarcopenia (AWGS) 2019 criteria. US predictors included muscle thickness (MT) of the rectus femoris (RF), vastus lateralis and gastrocnemius medialis (GM); pennation angle; and RF cross-sectional area (CSA). Analysis included Spearman's correlation (ρ), multivariable linear regression (B) and receiver operating characteristic (ROC) curves.
resultsThe cohort (n = 48; 47.9% women; median age 19.5 years, interquartile range [IQR] 12.3-26.8) had a 100% prevalence of obesity (median BMI 27.1 kg/m
conclusionsSarcopenia affects 52.1% of patients with PWS, with 20.8% meeting criteria for severe sarcopenia. Ultrasound of the gastrocnemius medialis is a valid, radiation-free predictor of skeletal muscle mass and serves as a practical diagnostic tool for sarcopenic obesity in PWS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.